Delcath Systems, Inc. (DCTH) is a medical technology company incorporated in April 1988 and based out of New York. This innovative company specializes in the design, development, and commercialization of a range of treatments for patients with advanced diseases in the liver. The focus of Delcath Systems, Inc. is to pioneer drug delivery systems that address the limitations of existing cancer treatments, particularly chemotherapy, to extend and improve the lives of patients.
The company's flagship product, CHEMOSAT® or Hepatic CHEMOSAT® Delivery System, offers a novel approach to treating cancer. It isolates the circulatory system of the liver in-order to administer high-dose chemotherapy, directly treating the liver and minimizing systemic exposure to the drug. This ground-breaking technique enables oncologists to treat liver cancers that are unresponsive to standard treatments, or are not suitable for surgical intervention. Moreover, it minimizes the negative side-effects, traditionally associated with systemic chemotherapy treatments.
Over the years, Delcath Systems, Inc. has led efforts to revolutionize patient care with its innovative drug delivery systems, transforming the lives of thousands of patients. To this end, the company engages in rigorous research, development, and clinical trials, collaborating with leading institutions and health professionals around the world.
The company's management consists of experienced professionals in the fields of medicine, biotechnology, and finance, which fosters an environment of innovation and growth. They are committed to driving the company's focus on research and development while ensuring fiscal responsibility and increasing shareholder value.
Delcath Systems, Inc. also places high emphasis on collaborative partnerships, believing that such efforts not only raise their productivity but also fuel the advancements in healthcare. They partner with a variety of entities ranging from academic hospitals, research institutes to pharmaceutical companies, with the aim to further refine their therapeutic approaches and expand their treatments’ reach.
Delcath Systems, Inc. continues to occupy a distinctive space in the oncology domain, aimed at improving patient outcomes and reducing the burden of cancer. Their advanced technological approaches have carved out their unique position in the global medical field, defining them as a forerunner in the scenario of liver disease management. As they move into the future, they are poised to continue to play a significant role in the way patients with advanced liver diseases are treated, contributing to the evolution of cancer care, and improving patients’ quality of life.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Delcath Systems, Inc. (DCTH), a medical device company focused on interventional oncology, is gaining investor interest due to its HEPZATO KIT for liver cancer treatment. With a current stock price of $16.25 and an average analyst target price of $24.00, the company shows a potential upside of 47.69%. Delcath's strong revenue growth, positive analyst sentiment, and commitment to clinical trials position it as a promising investment in the oncology device market.
Delcath Systems (DCTH) has significantly outperformed its Medical sector peers this year, with a 62.8% year-to-date gain compared to the sector's average of 2.4%. The company holds a Zacks Rank #2 (Buy) and has seen its full-year earnings estimate increase by 80.7% in the past quarter, indicating a strong improving outlook. Another strong performer in the sector is Encompass Health (EHC), which has gained 15.4% year-to-date.
Delcath Systems, Inc. (DCTH) reported Q2 earnings of $0.07 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.16 per share, and also surpassed revenue expectations with $29.13 million. The company's stock has seen a 25.1% increase year-to-date, outperforming the S&P 500. While the short-term outlook for the stock, currently holding a Zacks Rank #3 (Hold), suggests it will perform in line with the market, investors are advised to monitor future earnings estimate revisions.
This article provides a liquidity mapping analysis for Delcath Systems Inc. (DCTH), indicating strong sentiment across all horizons and compelling upside potential. It details AI-generated institutional trading strategies for various risk profiles, including position, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis for support and resistance levels.
Delcath Systems, Inc. (NASDAQ:DCTH) has amended its bylaws to designate Delaware courts as the exclusive forum for internal corporate claims and federal district courts for claims under the Securities Act of 1933. This decision follows a recommendation from its Nominating and Corporate Governance Committee. The company also recently reported strong Q2 2026 revenues of $29.1 million, exceeding forecasts, driven by demand for its HEPZATO KIT, and raised its full-year revenue guidance.
Renaissance Technologies LLC reduced its stake in Delcath Systems (NASDAQ:DCTH) by 57.1% in the first quarter, selling over 200,000 shares but still retaining a significant holding. Despite this, other institutional investors have increased their positions. The company reported strong Q1 revenue and earnings, surpassing analyst estimates, and analysts maintain a "Moderate Buy" rating with an average price target of $23.17, although some valuation and execution risks remain due to the stock nearing its 52-week high and projected near-term losses.